As customers prepare for the federal health law’s fourth open enrollment to open next week, the Affordable Care Act faces a big test with dramatic increases in policy premiums and fewer options as some insurers are pulling out of the marketplace.
Until this week, when big increases in insurance premiums were unveiled for next year, the federal health law has not been a major issue in the presidential election.
Supporters of “death with dignity” have succeeded in legalizing medical aid-in-dying in five states by convincing voters, lawmakers and courts that terminally ill patients have the right to die without suffering intractable pain in their final days or weeks.
SACRAMENTO, Calif.— The “public option,” which stoked fierce debate in the run-up to the Affordable Care Act, is making a comeback — at least among Democratic politicians.
Will Medicaid expansion save the country money as people stop using expensive emergency rooms for primary care?
Not in the first years, said a study published Wednesday online in the New England Journal of Medicine.
Rate hikes are likely on the way for plans offered on the health law’s online exchanges, or marketplaces. Consumers’ out-of-pocket costs are expected to climb, and some major insurers are pulling out.
Health care finally came up as an issue in the second presidential debate in St. Louis Sunday night. But the discussion may have confused more than clarified the issue for many voters.
The goal is lofty and expansive: to cure, prevent or manage all known diseases by the end of the century.
An overwhelming majority of Americans favor government action to restrain prescription drug prices, according to a poll released Thursday.
Eighty-two percent of those polled said they want Medicare to negotiate prices with the companies, which Congress does not allow. Seventy-eight percent favored limiting the amount companies can charge for high-cost drugs, such as those that fight cancer or hepatitis, according to the poll from the Kaiser Family Foundation.
Rising concerns about spending on prescription drugs that treat rare diseases are not justified, according to a new analysis in the journal Health Affairs.
